Edison Issues Initiation on Silence Therapeutics (SLN)

Jul 25, 2016, 08:49 ET from Edison Investment Research

LONDON, July 25, 2016 /PRNewswire/ --

Silence Therapeutics is a leading RNA therapeutics development company, with proprietary RNA interference (RNAi) technology (AtuRNAi) and delivery systems (LipoPLEXes). RNAi can be harnessed to silence the expression of any disease-causing protein. The basic rationale is simple: find any gene in the genome that is causing problems and synthesise an RNA molecule to shut down or upregulate the gene as necessary. Silence has an extensive genetic toolkit that addresses the technical challenges of delivery and therefore could offer 'multiple shots at goal', ie a broad range of potential indications. Silence is well funded following a fund-raising of £38.9m in 2015 to progress its early-stage technology.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We do not assign a fair value to Silence at this stage because its focus is currently on its preclinical pipeline and developing partnerships for its broader IP portfolio. We believe Silence offers one of the broadest ranges of RNA technologies in the sector, which could provide significant upside potential if the company executes its strategy. The company is well-funded following a £38.9m (net) fund-raising in 2015.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: 


Dr Linda Pomeroy              
Edison Investment Research        
+44(0)20-3077-5738

Lala Gregorek 
Edison Investment Research  
+44(0)20-3681-2527
healthcare@edisongroup.com

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn:    http://www.linkedin.com/company/edison-investment-research

Twitter:    http://www.twitter.com/Edison_Inv_Res

YouTube:    http://www.youtube.com/edisonitv

Google+:    https://plus.google.com/105425025202328783163/posts

SOURCE Edison Investment Research